TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32497440

Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI, Acthar® Gel) as adjunctive therapy along with DMARDs and glucocorticoids
Number of subjects: 0

Group type: COMPARATOR
Intervention: DMARDs and glucocorticoids alone (control group)
Number of subjects: 0
Study: 32497499

Group type: EXPERIMENTAL
Intervention: T cells from human bladder tumors and non-malignant tissue
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Single-cell RNA and paired T cell receptor (TCR) sequencing
Number of subjects: 7
Study: 32497600

Group type: EXPERIMENTAL
Intervention: Poor postural control
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Moderate postural control
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Using a walking aid in the acute phase
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Fall at the stroke unit
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Recurrent falls
Number of subjects: 504
Study: 32498033

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day on 5 consecutive days at baseline and on 3 consecutive days 12 months later)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day on 3 days; ≥12 months apart)
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Alemtuzumab exposure timing
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Alemtuzumab exposure and autoimmune thyroid adverse events
Number of subjects: 972

Group type: EXPERIMENTAL
Intervention: Annualized relapse rate post alemtuzumab
Number of subjects: 972
Study: 32498100

Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (eFTR)
Number of subjects: 367
Study: 32498621

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Mellitus (T2D)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Normal-weight and obese controls without diabetes mellitus
Number of subjects: 411
Study: 32499013

Group type: EXPERIMENTAL
Intervention: Increased alpha power
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Increased alpha band connectivity
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Impaired structural connectivity (increased radial diffusivity)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Frontal slow-wave activity (SWA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Reduction in connectivity
Number of subjects: 70
Study: 32499089

Group type: EXPERIMENTAL
Intervention: Nursing care procedures (NCP)
Number of subjects: 340
Study: 32499241

Group type: EXPERIMENTAL
Intervention: Non-myeloablative conditioning regimen (low-dose total body irradiation +/- fludarabine or clofarabine) followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus
Number of subjects: 1720
Study: 32499275

Group type: EXPERIMENTAL
Intervention: Panenteric capsule endoscopy (CE)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Magnetic resonance enterography (MRE) and/or ileocolonoscopy (IC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Magnetic resonance enterography (MRE)
Number of subjects: 99
Study: 32499329

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) measured with an implanted intraocular telemetry sensor
Number of subjects: 22
Study: 32499388

Group type: EXPERIMENTAL
Intervention: Child-reported PCSI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent-reported PCSI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall parent-child agreement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postinjury ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 0
Study: 32499730

Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS) administered for 6 weeks (5 days a week for the first 3 weeks, then 2 days a week for the next 3 weeks) in the dorsolateral prefrontal cortex.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed in the abstract).
Number of subjects: 90
Study: 32500206

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin and Cyclophosphamide (AC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined Paclitaxel and Carboplatin
Number of subjects: 0
Study: 32500294

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone or prednisolone
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1874
Study: 32500374

Group type: EXPERIMENTAL
Intervention: 3D gait analysis during free treadmill walking in people with MS
Number of subjects: 35

Group type: COMPARATOR
Intervention: 3D gait analysis during free treadmill walking in healthy controls
Number of subjects: 35
Study: 32500515

Group type: EXPERIMENTAL
Intervention: Panda-Nerve Block app
Number of subjects: 29
Study: 32500620

Group type: EXPERIMENTAL
Intervention: Intra-articular autologous bone marrow aspirate (BMA) injections
Number of subjects: 10
Study: 32501274

Group type: COMPARATOR
Intervention: Black/African American-focused campaign
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hispanic/Latino-focused campaign
Number of subjects: 0

Group type: COMPARATOR
Intervention: Black/African American-focused campaign post-scandal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hispanic/Latino-focused campaign post-scandal
Number of subjects: 0
Study: 32501275

Group type: EXPERIMENTAL
Intervention: Exergame intervention study
Number of subjects: 1632
Study: 32501454

Group type: EXPERIMENTAL
Intervention: High-dose anakinra (5 mg/kg twice a day intravenously)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard treatment (200 mg hydroxychloroquine twice a day and 400 mg lopinavir with 100 mg ritonavir twice a day)
Number of subjects: 45
Study: 32501528

Group type: EXPERIMENTAL
Intervention: Filanesib in combination with pomalidomide and dexamethasone
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study: 32501595

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10680
Study: 32501945

Group type: EXPERIMENTAL
Intervention: Patients with DSPN
Number of subjects: 48
Study: 32502219

Group type: EXPERIMENTAL
Intervention: United Nations Istanbul Protocol (UNIP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Validated pain screen (Brief Pain Inventory-Short Form [BPISF])
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference standard (pain specialist evaluation)
Number of subjects: 20
Study: 32502267

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily
Number of subjects: 624
Study: 32502272

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) - 2 initial doses
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) - 1 additional dose
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) - 2 additional doses
Number of subjects: 70
Study: 32502277

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D <50 nmol/l)
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Severe vitamin D deficiency (25(OH)D <25 nmol/l)
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Low 25(OH)D serum level
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Vitamin D levels (seasonal influence)
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: High BMI and dark-skinned ethnicities
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: 25(OH)D serum level
Number of subjects: 1382
Study: 32502336

Group type: EXPERIMENTAL
Intervention: BAY 1895344
Number of subjects: 0
Study: 32502439

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32502506

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (Carboplatin/etoposide and cyclophosphamide/etoposide regimens, 4 cycles every 3 weeks) followed by radiation therapy (RT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Radiation therapy (18 Gy craniospinal RT for metastatic tumors, whole brain RT for basal ganglia tumors, or whole ventricular RT followed by 12.6 Gy boost RT)
Number of subjects: 41
Study: 32502854

Group type: EXPERIMENTAL
Intervention: Increased nasal resistance (measured by 4-phase rhinomanometry)
Number of subjects: 126
Study: 32503441

Group type: EXPERIMENTAL
Intervention: Baseline assessment including self-administered PA and ST questionnaires and standardized measurement of blood pressure, waist circumference, and blood parameters; no treatment or intervention after 5 weeks
Number of subjects: 175
Study: 32503469

Group type: EXPERIMENTAL
Intervention: Nivolumab and entinostat (2 mg/m2)
Number of subjects: 0
Study: 32503476

Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment using a broad neuropsychological test battery
Number of subjects: 1
Study: 32503548

Group type: EXPERIMENTAL
Intervention: 3-item version of the Lee Fatigue Scale (LFS)
Number of subjects: 525

Group type: COMPARATOR
Intervention: 5-item version of the Lee Fatigue Scale (LFS)
Number of subjects: 525
Study: 32503583

Group type: EXPERIMENTAL
Intervention: Quality of care (QoC) indicators in ICU
Number of subjects: 396

Group type: COMPARATOR
Intervention: Ventilated ICU patients
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 396
Study: 32503811

Group type: EXPERIMENTAL
Intervention: Medical compression therapy (classes I and II)
Number of subjects: 94
Study: 32503866

Group type: EXPERIMENTAL
Intervention: TeGeCoach - a 12-month home-based exercise programme consisting of telemonitored intermittent walking exercise with medical supervision and telephone health coaching.
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Usual care - information leaflets and access to supervised exercise programmes, physical therapy, and healthy lifestyle programmes.
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: TeGeCoach
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1760
Study: 32503869

Group type: COMPARATOR
Intervention: False-positive group
Number of subjects: 130

Group type: COMPARATOR
Intervention: True-positive group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study: 32503947

Group type: EXPERIMENTAL
Intervention: murlentamab treatment
Number of subjects: 28
Study: 32503950

Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab combination therapy
Number of subjects: 4
Study: 32504089

Group type: EXPERIMENTAL
Intervention: Interferon-γ Release Assay
Number of subjects: 0
Study: 32504219

Group type: EXPERIMENTAL
Intervention: Second-line treatment
Number of subjects: 1806
Study: 32504369

Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy with Billroth II reconstruction (SGB2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nongastrectomized in-house relatives (Control)
Number of subjects: 14
Study: 32504533

Group type: EXPERIMENTAL
Intervention: Ultrasound activity index consisting of bowel wall thickness and colour Doppler
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ultrasound activity index
Number of subjects: 164
Study: 32504550

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: [sorafenib + vorinostat]
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neratinib alone
Number of subjects: 0
Study: 32504883

Group type: EXPERIMENTAL
Intervention: Fasting (prolonged fast from 18.00 h to 20.00 h the next day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 23
Study: 32505869

Group type: EXPERIMENTAL
Intervention: c-FLOW (Ornim Medical) monitoring
Number of subjects: 21
Study: 32506182

Group type: EXPERIMENTAL
Intervention: PCI (Percutaneous Coronary Intervention)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: PS1 (high resting coronary flow, dominantly LAD lesions)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: PS3 (non-LAD lesions with low hyperemic Pd)
Number of subjects: 364
Study: 32506203

Group type: EXPERIMENTAL
Intervention: Continuous recordings of ambient sound using a smartphone to track auditory signatures of breaths
Number of subjects: 50
Study: 32506317

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily (BID), with adjustments to 10 mg BID permitted post-month 1.
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID, with adjustments to 10 mg BID permitted post-month 1.
Number of subjects: 686
Study: 32506358

Group type: EXPERIMENTAL
Intervention: Electromuscular stimulation (EMS) for wrist flexors on nonparetic limb, 30 sessions for 6 weeks (60 min/session, 30 min EMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for nonparetic limb, 30 sessions for 6 weeks (60 min/session, 30 min TENS)
Number of subjects: 30
Study: 32506369

Group type: EXPERIMENTAL
Intervention: Intrathecal trastuzumab
Number of subjects: 34
Study: 32506428

Group type: EXPERIMENTAL
Intervention: Predictive model 1 (logistic regression)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Predictive model 2 (logistic regression)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Predictive model 3 (logistic regression)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Biological senescence group
Number of subjects: 1002
Study: 32506485

Group type: EXPERIMENTAL
Intervention: Cell surface vimentin (CSV) positive circulating tumor cells (CTC) monitoring
Number of subjects: 93
Study: 32506695

Group type: EXPERIMENTAL
Intervention: Induction therapy with golimumab
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with golimumab
Number of subjects: 102
Study: 32507018

Group type: EXPERIMENTAL
Intervention: Color-Duplex Ultrasound (DUS)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Computed Tomography-Aortography (CTA)
Number of subjects: 539
Study: 32507378

Group type: EXPERIMENTAL
Intervention: ACCESS integrated care for patients with severe psychotic disorders
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Patients with substance dependence
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ACCESS integrated care
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Comorbid substance use dependence
Number of subjects: 312
Study: 32507565

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dorsal penile nerve block (DPNB)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Caudal epidural block (CEB)
Number of subjects: 26
Study: 32507584

Group type: EXPERIMENTAL
Intervention: Young-child formula (YCF) consumption after age 10 months
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Current YCF consumption at age 24 months
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Prolonged YCF consumption (>12 months)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Increasing daily volume of YCF consumed at age 24 months
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Current or past YCF use
Number of subjects: 561
Study: 32507854

Group type: EXPERIMENTAL
Intervention: DEBIRI plus mFOLFOX6
Number of subjects: 57
Study: 32507905

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (PoCUS) for hydronephrosis
Number of subjects: 413
Study: 32508029

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg + gefitinib 250 mg (Cohort A)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Apatinib 250 mg + gefitinib 250 mg (Cohort B)
Number of subjects: 13
Study: 32508063

Group type: EXPERIMENTAL
Intervention: Tocilizumab with methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study: 32508188

Group type: EXPERIMENTAL
Intervention: Activities Scale for Kids Performance
Number of subjects: 0
Study: 32508541

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravenous adenosine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Saline (single bolus dose)
Number of subjects: 31
Study: 32508738

Group type: EXPERIMENTAL
Intervention: Paired Associative Stimulation (PAS) for 2 months (28 sessions in total, 5 times a week for the first 2 weeks and 3 times a week thereafter)
Number of subjects: 5
Study: 32508818

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIV) of rhIL-15 at 2 mcg/kg/day
Number of subjects: 0
Study: 32509320

Group type: EXPERIMENTAL
Intervention: Recovering Together (RT) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Minimally Enhanced Usual Care (MEUC)
Number of subjects: 20
Study: 32509319

Group type: EXPERIMENTAL
Intervention: Valsalva assist device
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 34
Study: 32509322

Group type: EXPERIMENTAL
Intervention: GP_Posit intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 32509392

Group type: EXPERIMENTAL
Intervention: Sorafenib with celecoxib (SoraCele)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 116
Study: 32509978

Group type: EXPERIMENTAL
Intervention: South Asian maternal ethnicity
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: West Asian/North African maternal ethnicity
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: East Asian maternal ethnicity
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Longer breastfeeding duration
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Daily cow's milk intake >2 cups
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Current infant formula use
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Bottle use beyond 15 months
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Meat consumption
Number of subjects: 1851
Study: 32510046

Group type: EXPERIMENTAL
Intervention: High load treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low load treatment
Number of subjects: 72
Study: 32511251

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1,000 mg) infusion on the first day of treatment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1,000 mg) infusion
Number of subjects: 92
Study: 32511514

Group type: EXPERIMENTAL
Intervention: Nebulized in-line endotracheal dornase alfa co-administered with albuterol
Number of subjects: 5
Study: 32511534

Group type: EXPERIMENTAL
Intervention: Inhalation of Nitric Oxide (NO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no inhalation of NO)
Number of subjects: 0
Study: 32511695

Group type: EXPERIMENTAL
Intervention: Oral capsulized fecal microbiota transplantation (FMT) for 2 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Post-FMT antibiotics
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPE carriers who achieved eradication
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CPE carriers who failed treatment
Number of subjects: 15
Study: 32511794

Group type: EXPERIMENTAL
Intervention: Papilla-related variables (morphology)
Number of subjects: 658
Study: 32511983

Group type: EXPERIMENTAL
Intervention: Tafasitamab plus lenalidomide
Number of subjects: 81
Study: 32512291

Group type: EXPERIMENTAL
Intervention: Valsartan (titrated to blood pressure up to a maximum of 160 mg bid)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 651
Study: 32512539

Group type: EXPERIMENTAL
Intervention: Morbidity secondary to stroke at 6 months
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes, cognitive and functional assessments
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Baseline, 3-month, and 6-month assessments
Number of subjects: 500
Study: 32512806

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) levels
Number of subjects: 579
Study: 32513113

Group type: EXPERIMENTAL
Intervention: VPIA analgesic infusion pump
Number of subjects: 19
Study: 32513121

Group type: EXPERIMENTAL
Intervention: Physical activity measured by an ankle mounted pedometer for 5 days, and physical tests measuring strength, balance, and walking speed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaires assessing various factors related to fall risk.
Number of subjects: 0
Study: 32513178

Group type: EXPERIMENTAL
Intervention: Standard of care with advanced cardiac imaging including echocardiography with deformation analysis and cardiovascular magnetic resonance (CMR) with T1 parametric mapping before and after AVR.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical AVR with myocardial biopsy for histological validation.
Number of subjects: 0
Study: 32513204

Group type: EXPERIMENTAL
Intervention: Included patients (70 patients)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Omitted patients (204 patients)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Reasons for omission
Number of subjects: 279
Study: 32513578

Group type: EXPERIMENTAL
Intervention: Flavor identification test in Ob patients
Number of subjects: 420

Group type: COMPARATOR
Intervention: Flavor identification test in NW subjects
Number of subjects: 420

Group type: COMPARATOR
Intervention: Flavor identification test in OW subjects
Number of subjects: 420
Study: 32513801

Group type: EXPERIMENTAL
Intervention: Meropenem 40 mg/kg/dose every 8 hours as a 4-hour infusion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Meropenem 110 mg/kg/day as a continuous infusion
Number of subjects: 57
Study: 32514369

Group type: EXPERIMENTAL
Intervention: Healthy Summer Learners (HSL) program
Number of subjects: 180

Group type: COMPARATOR
Intervention: 21C (control group)
Number of subjects: 180
Study: 32514382

Group type: EXPERIMENTAL
Intervention: Serious Game (SG) designed for nurse training
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Serious Game (SG)
Number of subjects: 71
Study: 32514439

Group type: EXPERIMENTAL
Intervention: Chloroquine plus prednisone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Azathioprine plus prednisone
Number of subjects: 57
Study: 32514450

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 (SGLT2) inhibitors for 12 weeks
Number of subjects: 0
Study: 32514599

Group type: EXPERIMENTAL
Intervention: Persistent AKI
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Transient AKI
Number of subjects: 1545
Study: 32514670

Group type: EXPERIMENTAL
Intervention: Day-case robotic partial nephrectomy (RPN)
Number of subjects: 82
Study: 32514794

Group type: EXPERIMENTAL
Intervention: Nasal glucagon (NG) 3 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intramuscular glucagon (IMG) 1 mg
Number of subjects: 66